1. Home
  2. ETV vs HROW Comparison

ETV vs HROW Comparison

Compare ETV & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

ETV

Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

N/A

Current Price

$15.16

Market Cap

1.7B

Sector

Finance

ML Signal

N/A

HROW

Harrow Inc.

N/A

Current Price

$32.97

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ETV
HROW
Founded
N/A
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2005
2008

Fundamental Metrics

Financial Performance
Metric
ETV
HROW
Price
$15.16
$32.97
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$69.86
AVG Volume (30 Days)
131.4K
426.1K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
71.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$31.62
Revenue Next Year
N/A
$50.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.13
$28.54
52 Week High
$15.49
$54.98

Technical Indicators

Market Signals
Indicator
ETV
HROW
Relative Strength Index (RSI) 42.98 34.42
Support Level $14.90 $32.74
Resistance Level $14.99 $36.37
Average True Range (ATR) 0.18 1.33
MACD -0.04 -0.44
Stochastic Oscillator 6.36 21.33

Price Performance

Historical Comparison
ETV
HROW

About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: